Nanexa AB (NANEXA) - Total Assets
Based on the latest financial reports, Nanexa AB (NANEXA) holds total assets worth Skr166.70 Million SEK (≈ $17.94 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Nanexa AB investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Nanexa AB - Total Assets Trend (2014–2025)
This chart illustrates how Nanexa AB's total assets have evolved over time, based on quarterly financial data. Check cash flow quality index of Nanexa AB to evaluate the quality of earnings relative to operating cash generation.
Nanexa AB - Asset Composition Analysis
Current Asset Composition (December 2025)
Nanexa AB's total assets of Skr166.70 Million consist of 38.8% current assets and 61.2% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 5.9% |
| Accounts Receivable | Skr5.70 Million | 4.1% |
| Inventory | Skr128.00K | 0.1% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr74.31 Million | 53.8% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Nanexa AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Nanexa AB market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nanexa AB's current assets represent 38.8% of total assets in 2025, an increase from 0.2% in 2014.
- Cash Position: Cash and equivalents constituted 5.9% of total assets in 2025, up from 0.1% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 53.0% of total assets, a decrease from 99.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 53.8% of total assets.
Nanexa AB Competitors by Total Assets
Key competitors of Nanexa AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
SIMCERE PHARMAC. GRP LTD
F:S2P
|
Germany | €14.73 Billion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥11.13 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
Nanexa AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.06 | 3.53 | 1.16 |
| Quick Ratio | 2.06 | 3.53 | 1.28 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr41.09 Million | Skr40.58 Million | Skr4.38 Million |
Nanexa AB - Advanced Valuation Insights
This section examines the relationship between Nanexa AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.38 |
| Latest Market Cap to Assets Ratio | 0.56 |
| Asset Growth Rate (YoY) | 50.4% |
| Total Assets | Skr138.14 Million |
| Market Capitalization | $77.75 Million USD |
Valuation Analysis
Below Book Valuation: The market values Nanexa AB's assets below their book value (0.56x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Nanexa AB's assets grew by 50.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Nanexa AB (2014–2025)
The table below shows the annual total assets of Nanexa AB from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr138.14 Million ≈ $14.87 Million |
+50.45% |
| 2024-12-31 | Skr91.82 Million ≈ $9.88 Million |
-30.57% |
| 2023-12-31 | Skr132.26 Million ≈ $14.23 Million |
-22.29% |
| 2022-12-31 | Skr170.19 Million ≈ $18.32 Million |
+3.15% |
| 2021-12-31 | Skr165.00 Million ≈ $17.76 Million |
+207.31% |
| 2020-12-31 | Skr53.69 Million ≈ $5.78 Million |
+51.51% |
| 2019-12-31 | Skr35.44 Million ≈ $3.81 Million |
+27.02% |
| 2018-12-31 | Skr27.90 Million ≈ $3.00 Million |
-15.88% |
| 2017-12-31 | Skr33.16 Million ≈ $3.57 Million |
+61.08% |
| 2016-12-31 | Skr20.59 Million ≈ $2.22 Million |
+164.18% |
| 2015-12-31 | Skr7.79 Million ≈ $838.69K |
+201.32% |
| 2014-12-31 | Skr2.59 Million ≈ $278.34K |
-- |
About Nanexa AB
Nanexa AB (publ), a pharmaceutical company, develops injectable drug products in the Nordic countries, Europe, Asia, and North America. The company offers PharmaShell, a drug delivery system based on atomic layer deposition coating technology for controlled release of various types of active pharmaceutical substances. It also develops NEX-22, a glucagon-like peptide-1 analogue liraglutide that ha… Read more